Cultural advice

The Australian National University acknowledges, celebrates and pays our respects to the Ngunnawal and Ngambri people of the Canberra region and to all First Nations Australians on whose traditional lands we meet and work, and whose cultures are among the oldest continuing cultures in human history.

Aboriginal and Torres Strait Islander peoples are advised that ANU Library collections may include images, names, voices, and other representations of deceased persons.

Material in the collection may contain terms, language or views that reflect the period in which the item was created and may be considered inappropriate today.

Assessing migraine patients with multifocal pupillographic objective perimetry

dc.contributor.authorAli, Eman
dc.contributor.authorCarle, Corinne Frances
dc.contributor.authorLueck, Christian
dc.contributor.authorKolic, Maria
dc.contributor.authorMaddess, Ted
dc.date.accessioned2022-11-02T02:49:52Z
dc.date.available2022-11-02T02:49:52Z
dc.date.issued2021
dc.date.updated2021-11-28T07:26:05Z
dc.description.abstractBackground: To establish the effects of stimulating intrinsically-photosensitive retinal ganglion cells (ipRGCs) on migraine severity, and to determine if migraine produces objectively-measured visual field defects. Methods: A randomized, open labelled, crossover study tested migraineurs and normal controls using multifocal pupillographic objective perimetry (mfPOP) with 44 test-regions/eye. A slow blue protocol (BP) stimulated ipRGCs, and a fast yellow protocol (YP) stimulated luminance channels. Migraine diaries assessed migraine severity. Per-region responses were analyzed according to response amplitude and time-to-peak. Results: Thirty-eight migraineurs (42.0 ± 16.5 years, 23 females) and 24 normal controls (39.2 ± 15.2 years, 14 females) were tested. The proportion of subjects developing a migraine did not differ after either protocol, either during the 1st day (odds ratio 1.0; 95% confidence interval 0.2–4.4, p = 0.48) or during the first 3 days after testing (odds ratio 0.8; 95% confidence interval 0.3–2.1, p = 0.68). Migraine days/week did not increase following testing with either protocol in comparison to the baseline week (1.4 ± 1.6 pre-testing (mean ± SD), 1.3 ± 1.4 post-BP, and 1.3 ± 1.2 post-YP; p = 0.96), neither did other measures of severity. Migraine occurring up to 2 weeks before testing significantly lowered amplitudes, − 0.64 ± 0.14 dB (mean ± SE), while triptan use increased amplitudes by 0.45 ± 0.10 dB, both at p < 0.001. Conclusions: Stimulating ipRGCs did not affect migraine occurrence or severity. Pupillary response characteristics were influenced by the occurrence of a recent migraine attack and a history of triptan use.en_AU
dc.format.mimetypeapplication/pdfen_AU
dc.identifier.issn1471-2377en_AU
dc.identifier.urihttp://hdl.handle.net/1885/277935
dc.language.isoen_AUen_AU
dc.provenanceThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the dataen_AU
dc.publisherBioMed Centralen_AU
dc.relationhttp://purl.org/au-research/grants/arc/CE0561903en_AU
dc.rights© 2021 The authorsen_AU
dc.rights.licenseCreative Commons Attribution licenceen_AU
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en_AU
dc.sourceBMC Neurologyen_AU
dc.subjectMigraineen_AU
dc.subjectTrigeminovascular pathwayen_AU
dc.subjectMelanopsinen_AU
dc.subjectMultifocal pupillographyen_AU
dc.subjectPhotosensitivityen_AU
dc.titleAssessing migraine patients with multifocal pupillographic objective perimetryen_AU
dc.typeJournal articleen_AU
dcterms.accessRightsOpen Accessen_AU
local.bibliographicCitation.issue211en_AU
local.bibliographicCitation.lastpage12en_AU
local.bibliographicCitation.startpage1en_AU
local.contributor.affiliationAli, Eman, College of Health and Medicine, ANUen_AU
local.contributor.affiliationCarle, Corinne, College of Health and Medicine, ANUen_AU
local.contributor.affiliationLueck, Christian, College of Health and Medicine, ANUen_AU
local.contributor.affiliationKolic, Maria, College of Health and Medicine, ANUen_AU
local.contributor.affiliationMaddess, Ted, College of Health and Medicine, ANUen_AU
local.contributor.authoruidAli, Eman, u4798777en_AU
local.contributor.authoruidCarle, Corinne, u4117988en_AU
local.contributor.authoruidLueck, Christian, u1807496en_AU
local.contributor.authoruidKolic, Maria, u4385340en_AU
local.contributor.authoruidMaddess, Ted, u8103614en_AU
local.description.notesImported from ARIESen_AU
local.identifier.absfor320905 - Neurology and neuromuscular diseasesen_AU
local.identifier.absseo200101 - Diagnosis of human diseases and conditionsen_AU
local.identifier.ariespublicationa383154xPUB19627en_AU
local.identifier.citationvolume21en_AU
local.identifier.doi10.1186/s12883-021-02239-zen_AU
local.identifier.scopusID2-s2.0-85106947005
local.publisher.urlhttps://bmcneurol.biomedcentral.com/en_AU
local.type.statusPublished Versionen_AU

Downloads

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Assessing migraine.pdf
Size:
1.35 MB
Format:
Adobe Portable Document Format
Description: